Investment Overview - The company plans to invest up to 10 million RMB as a limited partner in the Shenzhen Yifeng Guangming Science City Seed Fund (tentative name) [1][2] - The fund aims to focus on strategic emerging industries, future industries, and key industries supported by the Shenzhen government, particularly in the biopharmaceutical and high-end medical device sectors [2][6] - The investment was approved by the company's board on August 26, 2025, and does not require shareholder approval [2] Partner Information - The general partner and fund manager is Shenzhen Yifeng Investment Management Enterprise (Limited Partnership), established in March 2012 with a registered capital of 100 million RMB [2][3] - Another partner, Shenzhen Yifeng Mingyuan Technology Co., Ltd., was established in September 2024 with a registered capital of 555,556 RMB [4] Fund Details - The fund is structured as a limited partnership with a target fundraising scale of 127.5 million RMB and a lifespan of ten years [5] - The management of the fund will be executed by Yifeng Capital, and the minimum contribution for limited partners is set at 1 million RMB [5] Impact on the Company - This investment aligns with the company's long-term development strategy and is expected to broaden investment channels, supporting sustainable and high-quality growth [6] - The collaboration with experienced partners is anticipated to enhance risk management and project quality, benefiting the company and its shareholders [6]
昭衍新药: 昭衍新药关于与专业投资机构合作参与投资设立基金的公告